Profilo
Colin Scott was Vice President of Clinical Research and Development for NovaBay Pharmaceuticals, Inc. from January 2006 to December 31, 2008.
From October 2004 to December 2005, he was Vice President-Drug Development for GlycoMimetics.
From June 2004 to September 2004, Dr. Scott was a Consultant to several biopharmaceutical companies.
From September 2002 to May 2004, he served as the Vice President-Clinical and Regulatory at Arriva Pharmaceuticals, Inc. From March 2001 to May 2002, Dr. Scott served as Vice President-Clinical of Emisphere Technologies, Inc. He received a Medical degree in Pulmonology and Infectious Diseases from Glasgow University in Scotland.
Precedenti posizioni note di Colin Scott
| Società | Posizione | Fine |
|---|---|---|
| NOVABAY PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 31/12/2008 |
| GLYCOMIMETICS, INC. | Corporate Officer/Principal | 01/12/2005 |
Arriva Pharmaceuticals, Inc.
 Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Direttore Tecnico/Scientifico/R&S | 01/05/2004 |
| EMISPHERE TECHNOLOGIES, INC. | Direttore Tecnico/Scientifico/R&S | 01/05/2002 |
Formazione di Colin Scott
| University of Glasgow | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| NOVABAY PHARMACEUTICALS, INC. | Health Technology |
| GLYCOMIMETICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Arriva Pharmaceuticals, Inc.
Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Health Technology |
Emisphere Technologies, Inc.
 Emisphere Technologies, Inc. Pharmaceuticals: MajorHealth Technology Emisphere Technologies, Inc. is a commercial stage specialty pharmaceutical company, which engages in the development of new formulations of existing products and chemical entities, using Eligen Technology. Its product pipelines include eligen B12, eligen12.com, eligen B12 information, and purchase eligen B12. The company was founded in 1986 and is headquartered in Roseland, NJ. | Health Technology |
- Borsa valori
- Insiders
- Colin Scott
